Rise Advisors LLC Purchases New Shares in Chemed Co. (NYSE:CHE)

Rise Advisors LLC purchased a new stake in Chemed Co. (NYSE:CHE) in the first quarter, Holdings Channel.com reports. The institutional investor purchased 40 shares of the company’s stock, valued at approximately $26,000.

A number of other hedge funds and other institutional investors have also modified their holdings of CHE. Norges Bank acquired a new position in shares of Chemed in the 4th quarter valued at $92,359,000. TD Asset Management Inc lifted its stake in Chemed by 164.3% in the 4th quarter. TD Asset Management Inc now owns 205,777 shares of the company’s stock worth $120,328,000 after acquiring an additional 127,934 shares in the last quarter. Massachusetts Financial Services Co. MA lifted its stake in Chemed by 121.5% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 203,096 shares of the company’s stock worth $118,760,000 after acquiring an additional 111,399 shares in the last quarter. International Assets Investment Management LLC purchased a new stake in Chemed in the 4th quarter worth about $430,970,000. Finally, Epoch Investment Partners Inc. lifted its stake in Chemed by 85.2% in the 4th quarter. Epoch Investment Partners Inc. now owns 152,162 shares of the company’s stock worth $88,977,000 after acquiring an additional 70,001 shares in the last quarter. Institutional investors and hedge funds own 95.85% of the company’s stock.

Chemed Price Performance

CHE opened at $533.44 on Friday. Chemed Co. has a fifty-two week low of $492.84 and a fifty-two week high of $654.62. The business has a 50-day moving average of $565.21 and a 200-day moving average of $590.33. The company has a market capitalization of $8.08 billion, a PE ratio of 28.71, a price-to-earnings-growth ratio of 2.19 and a beta of 0.46.

Chemed (NYSE:CHE) last posted its quarterly earnings results on Wednesday, April 24th. The company reported $4.68 earnings per share for the quarter, missing analysts’ consensus estimates of $5.09 by ($0.41). Chemed had a return on equity of 30.52% and a net margin of 12.36%. The firm had revenue of $589.23 million for the quarter, compared to analysts’ expectations of $587.18 million. On average, equities research analysts expect that Chemed Co. will post 21.54 earnings per share for the current fiscal year.

Chemed Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, June 18th. Stockholders of record on Thursday, May 30th were paid a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.30%. The ex-dividend date was Thursday, May 30th. Chemed’s dividend payout ratio (DPR) is presently 8.61%.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on CHE. StockNews.com raised Chemed from a “hold” rating to a “buy” rating in a research note on Saturday, May 4th. Oppenheimer increased their price objective on Chemed from $625.00 to $650.00 and gave the stock an “outperform” rating in a research note on Thursday, February 29th. Finally, Royal Bank of Canada reduced their price objective on Chemed from $712.00 to $697.00 and set an “outperform” rating for the company in a research note on Tuesday, May 21st.

Insider Transactions at Chemed

In other news, EVP Spencer S. Lee sold 2,000 shares of the firm’s stock in a transaction dated Thursday, March 28th. The stock was sold at an average price of $641.65, for a total transaction of $1,283,300.00. Following the completion of the sale, the executive vice president now directly owns 20,760 shares of the company’s stock, valued at approximately $13,320,654. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, EVP Spencer S. Lee sold 2,000 shares of the stock in a transaction dated Thursday, March 28th. The stock was sold at an average price of $641.65, for a total transaction of $1,283,300.00. Following the transaction, the executive vice president now owns 20,760 shares of the company’s stock, valued at approximately $13,320,654. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Kevin J. Mcnamara sold 4,000 shares of the stock in a transaction dated Thursday, May 16th. The shares were sold at an average price of $567.54, for a total value of $2,270,160.00. Following the transaction, the chief executive officer now directly owns 108,549 shares in the company, valued at approximately $61,605,899.46. The disclosure for this sale can be found here. Insiders sold 7,784 shares of company stock valued at $4,523,353 in the last three months. Corporate insiders own 3.32% of the company’s stock.

Chemed Profile

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.